MAZE
Maze Therapeutics, Inc.
36.73
+1.28 (+3.61%)
52w low 21.95
53.65 high
46.6% of range
Financial Analysis
| Ratio | Dec 22 | Dec 23 | Dec 24 | Dec 25 | Trend |
|---|---|---|---|---|---|
| Profitability | |||||
| Operating Margin | -- | -- | 34.4% | -- | |
| EBITDA Margin | -- | -- | 36.3% | -- | |
| Net Margin | -- | -- | 31.2% | -- | |
| FCF Margin | -- | -- | 44.7% | -- | |
| Returns | |||||
| Return on Equity | 40.7% | 26.9% | -16.8% | -36.9% | |
| Return on Assets | -76.6% | -140.4% | 21.7% | -33.0% | |
| Return on Inv Capital | 31.1% | 27.9% | -18.1% | -40.3% | |
| Liquidity | |||||
| Current Ratio | 5.11x | 2.09x | 9.76x | 15.50x | |
| Quick Ratio | 5.11x | 2.09x | 9.76x | 15.50x | |
| Cash Ratio | 4.81x | 1.79x | 9.52x | 8.39x | |
| Leverage | |||||
| Debt / Equity | -0.11x | -0.13x | -0.09x | 0.07x | |
| Equity Multiplier | -0.53x | -0.19x | -0.77x | 1.12x | |
| Efficiency | |||||
| Asset Turnover | 0.00x | 0.00x | 0.70x | 0.00x | |
| Effective Tax Rate | -- | -0.0% | 2.2% | -0.0% | |
| Op CF / Net Income | 0.86x | 0.86x | 1.45x | 0.85x | |
| Investment | |||||
| Capex / Revenue | -- | -- | 0.7% | -- | |
| R&D / Revenue | -- | -- | 49.8% | -- | |
| SG&A / Revenue | -- | -- | 15.8% | -- | |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
-100.0%